Orano - Annual Activity Report 2025 45 SITUATION AND ACTIVITIES OF THE COMPANY AND ITS SUBSIDIARIES DURING THE PAST FINANCIAL YEAR 2 The group’s businesses Orano Med’s ambition is to develop effective and targeted anticancer therapies in two strategic areas: ● developing innovative treatments using Orano Med’s lead-212 through scientific partnerships or 100% Orano Med projects; and ● building the production plants necessary to produce these lead-212 treatments in order to meet the needs of current clinical development and the potential future marketing of drugs subject to validation by the health authorities. ORANO MED’S ONCOLOGY R&D PIPELINE Discovery Indication PoC Pre-IND Phase 1 Phase 2/3 Program Partners AlphaMedix TM Undisclosed Undisclosed Neuroendocrine tumors 212Pb-GRPR Solid tumors (breast and prostate cancer) 212Pb-PSMA 212Pb CEA-PRIT Prostate cancer 212Pb DARPinMSLN Small-cell lung cancer 212Pb-PRRT Solid tumors (including ovarian cancer) 212Pb-PRRT Undisclosed target 212Pb DARPin Undisclosed target Undisclosed target Source: Orano 212Pb-DARPin-DLL3 MP0712 Solid tumors 212Pb-PRRT Several targets 212Pb-TAT Several targets Phage display platform Phage display platform Batteries Program In 2020, Orano decided to launch the “battery recycling” project by conducting R&D work with CEA Liten to develop an innovative process for recycling Lithium-ion electric vehicle batteries. A joint research laboratory was created in January 2020, located on the CEA site in Grenoble (France).
RkJQdWJsaXNoZXIy NzMxNTcx